Altimmune's pemvidutide reduces liver fat in 48-week Phase 2b MASH trial
ALT•Altimmune announced publication of 48-week Phase 2b IMPACT trial results showing pemvidutide significantly improved noninvasive measures of liver fat, inflammation and fibrosis versus placebo. Treatment also produced significant weight loss and generally favorable tolerability; the results support the ongoing Phase 3 PERFORMA trial.
1. Trial results published
Altimmune announced publication in The Lancet Gastroenterology & Hepatology of 48-week results from its Phase 2b IMPACT trial of pemvidutide in MASH. The findings, previously presented at The Liver Meeting, showed significant improvements versus placebo in noninvasive measures of liver fat, inflammation and fibrosis.
2. Phase 3 trial ongoing
Treatment also produced significant weight loss and was generally well tolerated. Altimmune said the results support its ongoing PERFORMA Phase 3 trial.
